Daily mycoprotein consumption for 1 week does not affect insulin sensitivity or glycaemic control but modulates the plasma lipidome in healthy adults: a randomised controlled trial.
Study Goal
The researchers aimed to determine the impact of substituting meat/fish with mycoprotein on insulin sensitivity, glycaemic control, and plasma lipoprotein composition in healthy adults.
Results Summary
Mycoprotein did not affect insulin sensitivity or glycaemic control but led to a coordinated reduction in circulating cholesterol-containing lipoproteins, including decreases in total plasma cholesterol, LDL-cholesterol, and HDL2-cholesterol.
Population
Twenty healthy adults.
Effective Dosage
Mycoprotein was consumed twice daily (lunch and dinner) as the primary protein source.
Duration
7 days.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
Mycoprotein consumption | decrease | acute postprandial glycaemic control | - | - | has been shown to improve | #1 |
Mycoprotein consumption | decrease | circulating cholesterol concentrations | - | - | decrease | #2 |
incorporating mycoprotein into the diet | no change | blood glucose responses | Twenty healthy adults | no significant change | no changes | #3 |
incorporating mycoprotein into the diet | no change | serum insulin responses | Twenty healthy adults | no significant change | no changes | #4 |
incorporating mycoprotein into the diet | no change | insulin sensitivity (IS) | Twenty healthy adults | no significant change | no changes | #5 |
incorporating mycoprotein into the diet | no change | 24 h glycaemic profiles | Twenty healthy adults | no significant change | no changes | #6 |
mycoprotein (MYC) as the primary source of dietary protein | decrease | Forty-five lipid concentrations of different lipoprotein fractions (VLDL, LDL, intermediate-density lipoprotein and HDL) | MYC group | 7-27 % | showed a coordinated decrease | #7 |
mycoprotein (MYC) as the primary source of dietary protein | decrease | Total plasma cholesterol | MYC group | 14-19 % | decreased to a larger degree | #8 |
mycoprotein (MYC) as the primary source of dietary protein | decrease | free cholesterol | MYC group | 14-19 % | decreased to a larger degree | #9 |
mycoprotein (MYC) as the primary source of dietary protein | decrease | LDL-cholesterol | MYC group | 14-19 % | decreased to a larger degree | #10 |
mycoprotein (MYC) as the primary source of dietary protein | decrease | HDL2-cholesterol | MYC group | 14-19 % | decreased to a larger degree | #11 |
mycoprotein (MYC) as the primary source of dietary protein | decrease | DHA | MYC group | 14-19 % | decreased to a larger degree | #12 |
mycoprotein (MYC) as the primary source of dietary protein | decrease | n-3 fatty acids | MYC group | 14-19 % | decreased to a larger degree | #13 |
Substituting meat/fish for mycoprotein twice daily for 1 week | no change | whole-body insulin sensitivity (IS) | - | - | did not modulate | #14 |
Substituting meat/fish for mycoprotein twice daily for 1 week | no change | glycaemic control | - | - | did not modulate | #15 |
Substituting meat/fish for mycoprotein twice daily for 1 week | decrease | plasma lipid composition | - | - | resulted in changes to | #16 |
Substituting meat/fish for mycoprotein twice daily for 1 week | decrease | circulating cholesterol-containing lipoproteins | - | - | reduction in | #17 |
Mycoprotein consumption has been shown to improve acute postprandial glycaemic control and decrease circulating cholesterol concentrations. We investigated the impact of incorporating mycoprotein into the diet on insulin sensitivity (IS), glycaemic control and plasma lipoprotein composition. Twenty healthy adults participated in a randomised, parallel-group trial in which they consumed a 7 d fully controlled diet where lunch and dinner contained either meat/fish (control group, CON) or mycoprotein (MYC) as the primary source of dietary protein. Oral glucose tolerance tests were performed pre- and post-intervention, and 24 h continuous blood glucose monitoring was applied throughout. Fasting plasma samples were obtained pre- and post-intervention and were analysed using quantitative, targeted NMR-based metabonomics. There were no changes within or between groups in blood glucose or serum insulin responses, nor in IS or 24 h glycaemic profiles. No differences between groups were found for 171 of the 224 metabonomic targets. Forty-five lipid concentrations of different lipoprotein fractions (VLDL, LDL, intermediate-density lipoprotein and HDL) remained unchanged in CON but showed a coordinated decrease (7-27 %; all P < 0·05) in MYC. Total plasma cholesterol, free cholesterol, LDL-cholesterol, HDL2-cholesterol, DHA and n-3 fatty acids decreased to a larger degree in MYC (14-19 %) compared with CON (3-11 %; P < 0·05). Substituting meat/fish for mycoprotein twice daily for 1 week did not modulate whole-body IS or glycaemic control but resulted in changes to plasma lipid composition, the latter primarily consisting of a coordinated reduction in circulating cholesterol-containing lipoproteins.